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 In conclusion, the conventional model of cell inactivation based on in 
vitro survival curves which can be described by the L-Q formalism is 
being complemented by complex mechanisms involving the cellular 
radiation response, interaction with other target cells, and the 
influence of the microenvironment and systemic factors. 
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Background: In 2010, we reported data on local control and early 
toxicity for theTARGIT-A trial of intraoperative radiotherapy after 
lumpectomy for early breastcancer (n = 2232, Vaidya et al, Lancet). 
Randomisation continued until a totalnumber of 3451 patients were 
included in June 2012. We present the updatedresults on local control 
and the first analysis of survival of the wholecohort. 
Methods: TARGIT-A was a randomised trial in patients >=45 years with 
invasive ductal carcinoma undergoing breast conserving surgery 
comparing standard fractionated whole breast EBRT (3-6 weeks) with 
single dose TARGIT (20 Gy)either given at the time of the primary 
operation (prepathology stratum) or ina delayed second procedure 
(post pathology stratum). The experimental arm mandated additional 
EBRT excluding a boost, if adverse features were detected on final 
pathology making this a “risk-adapted policy”. 3451, 2020 and 1222 
patients have a median follow-up of 2.5, 4 and 5 years, respectively. 
The primary outcome was ipsilateral within breast recurrence (IBR) 
with an absolute non-inferiority margin of 2.5% at 5 years and 
secondary outcome was survival. 
Results: 1721 patients were randomly allocated to receive TARGIT and 
1730 to EBRT. Primary events have increased from 13 to 34 since2010. 
For the primary outcome of ipsilateral breast recurrence, the absolute 
difference at 5-years was 2.0% (3.3% vs. 1.3%), which was higher with 
TARGIT; in prepathology the absolute difference in 5-year IBR was 1%; 
in post pathology it was 3.7%. For the secondary outcome, there was a 
non-significant trend for improved overall survival with TARGIT (HR = 
0.70) due to fewer non-breast cancer deaths (17 vs. 35, HR 0.47). 
Conclusion: Patients in the TARGIT-A trial have excellent 5 year 
outcomes (local control > 96%, overall survival >= 94%) in both arms of 
the trial. 
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Background: To assess the role of an intraoperative electron boost 
(IOERT) in combination with hypofractionated whole breast irradiation 
(WBI) in terms of in-breast tumor control and cosmeticoutcome. 
Methods: Starting in Jan 2011, a prospective multi-center single arm 
trial is conducted by the ISIORT. Patients receive an IOERT boost of 10 
Gy ( Dmax 11.1 Gy) followed by a WBI of 40.5 Gy in 15 fractions (2.7 
Gy single dose). 5-year in-breast-recurrence rates will be analyzed in 
3 different age groups (35–40y, 41-50y, >50y) and tested against the 
respective best published results from randomized prospective trials 
by the use of a sequential probability ratio test (SPRT). Acute 
reactions are assessed by CTC-scoring, late reactions according to 
LENT-SOMA criteria. Cosmesis is evaluated by a 5-point-Scoring System 
(van Limbergen, double evaluation) starting prior to WBI on the basis 
of repeated photodocumentation in standardized positions. 
Results: As of Jan2013, within six active institutions 327 patients have 
been recruited, 204 of them already in follow-up. Patient and tumor 
characteristics are summarized in Table 1.  
  
  
For IOERT, the median energy chosen was 6 MeV(range 4-12) with 
median tube diameters of 6 cm (3-8) and mean prescription depths of 
20 mm (13.8 SD), resulting in mean D90 volumes of 37 ml.  
Perioperatively, no major complications were observed. Four weeks 
after the end of WBI, 60 patients (29.8%) showed no reactions (CTC 0), 
130 patients (66.2%) presented with faint (CTC 1) and eight (4%) with 
moderate to brisk erythema (CTC 2),respectively. Four to five months 
after the end of treatment, late reactions according to LENT-SOMA 
criteria were assessed in 159 patients, all of them scored as grade 0. 
At one year post WBI, 74 patients still presented as grade 0, one 
patient as grade 1. 
Cosmesis was assessed postoperatively in 217 patients, 159 were 
evaluated 4-5 months and 75 one year after the end of WBI, 
respectively. Baseline appearance prior toWBI was scored as excellent 
(E0) in 31.8/17.5% (patients/doctors), good (E1) in 52/50.4%, 
moderate (E2) in 14.3/27.6%, bad (E3) in 1.4/4.5% and complication 
(E4) in 0.5/0%.  At 4 months post RT, there was a trend towards 
better rating:  E0: 34.6/21.3%; E1: 51.6/46.9%; E2: 12.6/27.3%,E 3: 
1.2/4.5%.  Results at 12 months follow-up were similar. 
At a median follow-up period of 12 months (3-16), no recurrence was 
noted. 
Conclusion: Tolerance of a combined IOERT / hypofractionated WBI 
regimen is excellent, acute reactions moderate and late reactions 
insignificant in short-term assessment. With regard to postoperative 
appearance, early cosmetic results are not impaired. Both tumor 
control and cosmetic outcome have to be evaluated on long-term 
follow-up. 
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